SCHOTT Pharma to Expand in the U.S. with New Prefillable Syringe Manufacturing Facility in Wilson, North Carolina

With $371 million investment, new site to add over 400 jobs to the region
First U.S. manufacturing facility to fill demand for domestic supply of glass and polymer prefillable syringes that deliver mRNA, GLP-1, and other therapies.

SCHOTT Pharma, a pioneer in pharmaceutical drug containment solutions and delivery systems, will build the first U.S. facility to manufacture prefillable polymer syringes required to meet the need for deep-cold storage and transportation of mRNA medications. In addition, the site will have the capability to produce glass prefillable syringes for GLP-1 therapies, for example to treat diseases such as diabetes or obesity. The project will add 401 jobs to the region and include a total investment of $371 million, with groundbreaking expected by the end of 2024, and projected operations starting in 2027.

24.03.2024, SCHOTT Pharma

Il materiale informativo del sito è registrato ed appartiene all´azienda o ai terzi che lo hanno fornitoe tutti i diritti sono riservati. Qualsiasi utente che accede a tale materiale può farlo solo ad uso personale e ne è anche responsabile. Ridistribuzione o altro uso commerciale di tale materiale è espressamente proibito. Nel caso in cui il materiale sia stato ceduto da terzi, l´utente concorda di rispettare questi termini di utilizzo specificati. Glass Global non garantisce la veridicità o l´esattezza del contenuto di alcuna informazione o di siti web esterni menzionati nelle stesse.

Should the content or the design of these sites violate third parties rights or legal prescriptions, we kindly ask you to send us a respective message without invoice or cost. We guarantee that passages where the claim is considered as justified will be removed immediately, without any necessity to involve any lawyer into this issue. We will reject any claim caused by submission of a honorary note in this regard without any prior contact and confirmation of the issueby us and we reserve the right ssue counter claim ourselves because of violation of aforesaid conditions.